201 related articles for article (PubMed ID: 30148441)
1. Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition.
Fioravanti A; Tenti S; Bacarelli MR; Damiani A; Li Gobbi F; Bandinelli F; Cheleschi S; Galeazzi M; Benucci M
Clin Exp Rheumatol; 2019; 37(2):293-300. PubMed ID: 30148441
[TBL] [Abstract][Full Text] [Related]
2. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
[TBL] [Abstract][Full Text] [Related]
3. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
[TBL] [Abstract][Full Text] [Related]
4. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade.
Makrilakis K; Fragiadaki K; Smith J; Sfikakis PP; Kitas GD
Clin Rheumatol; 2015 Mar; 34(3):419-27. PubMed ID: 24912961
[TBL] [Abstract][Full Text] [Related]
5. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
Kremer JM; Rigby W; Singer NG; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
Arthritis Rheumatol; 2018 Aug; 70(8):1200-1208. PubMed ID: 29575803
[TBL] [Abstract][Full Text] [Related]
6. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
11. Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy.
Hu W; Ding Y; Guan K; Zhang P; Su J; Zhang C; Li W; Lian C; Yang Q; Liu S; Li T
Clin Rheumatol; 2024 Jun; 43(6):1845-1853. PubMed ID: 38696116
[TBL] [Abstract][Full Text] [Related]
12. Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis?
Benucci M; Meacci F; Manfredi M; Gobbi FL; Infantino M; Ricci C; Sarzi-Puttini P; Atzeni F
Curr Rheumatol Rev; 2014; 10(2):131-5. PubMed ID: 25599685
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
Pablos JL; Navarro F; Blanco FJ; Román-Ivorra JA; Alonso A; Martín Mola E; Cantalejo M; Ercole L; Rivero N;
Clin Exp Rheumatol; 2019; 37(3):437-444. PubMed ID: 30299241
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study.
Choi IA; Sagawa A; Lee EY; Lee EB; Song YW
J Korean Med Sci; 2020 Jun; 35(22):e155. PubMed ID: 32508063
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
[TBL] [Abstract][Full Text] [Related]
16. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
[TBL] [Abstract][Full Text] [Related]
18. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.
Ormseth MJ; Yancey PG; Solus JF; Bridges SL; Curtis JR; Linton MF; Fazio S; Davies SS; Roberts LJ; Vickers KC; Kon V; Michael Stein C;
Arthritis Rheumatol; 2016 Sep; 68(9):2099-105. PubMed ID: 26991245
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
20. Serum Vaspin Levels Are Associated with the Development of Clinically Manifest Arthritis in Autoantibody-Positive Individuals.
Maijer KI; Neumann E; Müller-Ladner U; Drop DA; Ramwadhdoebe TH; Choi IY; Gerlag DM; de Hair MJ; Tak PP
PLoS One; 2015; 10(12):e0144932. PubMed ID: 26670468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
